ObsEva Competitors and Similar CompaniesClear all
ObsEva's competitors and similar companies include NIOX, Durect, Affimed N.V. and Amicus Therapeutics.
 ObsEva ObsEva is a speciality biopharmaceutical company developing drugs for womens reproductive medicine. |  NIOX NIOX (formerly Circassia) is a specialty biopharmaceutical company focused on developing novel immunotherapies |  Durect DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases. |  Affimed N.V. Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. |  Amicus Therapeutics Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases. | |
Founding Date | Founding Date 2012 | Founding Date 2006 | Founding Date N/A | Founding Date 2000 | Founding Date 2002 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Plan-les-Ouates, CH HQ Boston, US Sacramento, US | Locations Morrisville, US HQ Bad Homburg Vor Der Höhe, DE Uppsala, SE Morrisville, US | Locations Cupertino, US HQ | Locations Heidelberg, DE HQ | Locations Philadelphia, US HQ Northbridge, AU Pointe Claire, CA Paris, FR München, DE Dublin, IE Milano, IT see more |
Employees | Employees 811% decrease | Employees 91 | Employees 902% increase | Employees 76 | Employees 58415% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 340.9 m | Valuation ($) 45.3 m | Valuation ($) 52.5 m | Valuation ($) 3.4 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) £48.7m (FY, 2025) | Revenue (est.) $2m (FY, 2024) | Revenue (est.) €8.3m (FY, 2023) | Revenue (est.) $634.2m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods £11.1m (FY, 2025) | Cost of goods $78k (FY, 2024) | Cost of goods N/A | Cost of goods $72.9m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit £38.2m (FY, 2025) | Gross profit $2m (FY, 2024) | Gross profit €13m (FY, 2023) | Gross profit $561.3m (FY, 2025) |
Net income | Net income N/A | Net income £7m (FY, 2025) | Net income ($8.3m) (FY, 2024) | Net income (€105.9m) (FY, 2023) | Net income ($27.1m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 92.9m | Total funding raised $ 122.8m | Total funding raised $ 20m | Total funding raised N/A | Total funding raised $ 88m |
For sources of this data, please see the company profile
View Company Profiles
NIOX
HQ
Morrisville, US
Employees
91
NIOX (formerly Circassia) is a specialty biopharmaceutical company focused on developing novel immunotherapies
View companyDurect
HQ
Cupertino, US
Employees
90↑ 2% increase
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases.
View companyAffimed N.V.
HQ
Heidelberg, DE
Employees
76
Affimed is a NASDAQ-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies.
View companyAmicus Therapeutics
HQ
Philadelphia, US
Employees
584↑ 15% increase
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
View company